131
Participants
Start Date
January 31, 2006
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
Ziprasidone 80-160 mg/d
Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
Placebo
Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
Ziprasidone 160 mg/d
Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
The Lieber Center for Schizophrenia Research - Columbia University, New York
Nathan Kline Institute, Orangeburg
SUNY Downstate Medical Center, Brooklyn
Duke University - John Umstead Hospital, Butner
Medical College of Georgia, Augusta
Touchstone innovare, Grand Rapids
The Mech Center, Plano
University of New Mexico, Albuquerque
Corrigan Mental Health Center, Fall River
Collaborators (1)
Pfizer
INDUSTRY
Donald C. Goff, MD
OTHER